Ipratropium
- Generic Name
- Ipratropium
- Brand Names
- Atrovent, Combivent, Ipravent
- Drug Type
- Small Molecule
- Chemical Formula
- C20H30NO3
- CAS Number
- 60205-81-4
- Unique Ingredient Identifier
- GR88G0I6UL
- Background
Ipratropium is a quaternary ammonium derivative of atropine that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.
...
- Indication
Inhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.
Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.
...
- Associated Conditions
- Acute Exacerbation of Asthma, Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Nasal Congestion Associated With the Common Cold, Non-Allergic Rhinitis, Perennial Allergic Rhinitis (PAR), Rhinitis
- Associated Therapies
- -
Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2015-12-02
- Target Recruit Count
- 152
- Registration Number
- NCT02584738
- Locations
- 🇲🇽
Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico
The Effects of RPL554 on Top of Standard COPD Reliever Medications
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 36
- Registration Number
- NCT02542254
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02296047
- Locations
- 🇨🇳
Zhujiang Hospital,Southern Medical Universtiy, Guangzhou, Guangdong, China
Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02235428
Helium-3 MRI Imaging Study in COPD
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT02207452
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1118
- Registration Number
- NCT02177253
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 646
- Registration Number
- NCT02177344
Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02172443
Ipratropium Bromide in Peri-Operative COPD
- Conditions
- Interventions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 192
- Registration Number
- NCT01943552
- Locations
- 🇨🇳
244.2514.86002 Boehringer Ingelheim Investigational Site, Tianjin, China
🇨🇳244.2514.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China
🇨🇳244.2514.86009 Boehringer Ingelheim Investigational Site, Hangzhou, China
A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT01696214
- Locations
- 🇺🇸
Airway Research & Clinical Trials Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.